Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Leveraging a Redesigned Morbidity and Mortality Conference That Incorporates the Clinical and Educational Missions of Improving Quality and Patient Safety.

Tad-Y DB, Pierce RG, Pell JM, Stephan L, Kneeland PP, Wald HL.

Acad Med. 2016 Sep;91(9):1239-43. doi: 10.1097/ACM.0000000000001150.

PMID:
26983075
2.

Patient access to electronic health records during hospitalization.

Pell JM, Mancuso M, Limon S, Oman K, Lin CT.

JAMA Intern Med. 2015 May;175(5):856-8. doi: 10.1001/jamainternmed.2015.121. No abstract available.

PMID:
25751393
3.

Don't fuel the fire: decreasing intravenous haloperidol use in high risk patients via a customized electronic alert.

Pell JM, Cheung D, Jones MA, Cumbler E.

J Am Med Inform Assoc. 2014 Nov-Dec;21(6):1109-12. doi: 10.1136/amiajnl-2014-002777. Epub 2014 Jun 13.

4.

p38α MAPK regulates adult muscle stem cell fate by restricting progenitor proliferation during postnatal growth and repair.

Brien P, Pugazhendhi D, Woodhouse S, Oxley D, Pell JM.

Stem Cells. 2013 Aug;31(8):1597-610. doi: 10.1002/stem.1399.

5.

Ezh2 maintains a key phase of muscle satellite cell expansion but does not regulate terminal differentiation.

Woodhouse S, Pugazhendhi D, Brien P, Pell JM.

J Cell Sci. 2013 Jan 15;126(Pt 2):565-79. doi: 10.1242/jcs.114843. Epub 2012 Nov 30.

6.

BTB-Kelch protein Krp1 regulates proliferation and differentiation of myoblasts.

Paxton CW, Cosgrove RA, Drozd AC, Wiggins EL, Woodhouse S, Watson RA, Spence HJ, Ozanne BW, Pell JM.

Am J Physiol Cell Physiol. 2011 Jun;300(6):C1345-55. doi: 10.1152/ajpcell.00321.2010. Epub 2011 Mar 2.

7.
8.

Essential role for p38alpha MAPK but not p38gamma MAPK in Igf2 expression and myoblast differentiation.

Lovett FA, Cosgrove RA, Gonzalez I, Pell JM.

Endocrinology. 2010 Sep;151(9):4368-80. doi: 10.1210/en.2010-0209. Epub 2010 Jul 7.

PMID:
20610565
9.

Point:Counterpoint: IGF is/is not the major physiological regulator of muscle mass. Point: IGF is the major physiological regulator of muscle mass.

Stewart CE, Pell JM.

J Appl Physiol (1985). 2010 Jun;108(6):1820-1; discussion 1823-4; author reply 1832. doi: 10.1152/japplphysiol.01246.2009. Epub 2009 Nov 5. No abstract available.

10.

MEK5 and ERK5 are mediators of the pro-myogenic actions of IGF-2.

Carter EJ, Cosgrove RA, Gonzalez I, Eisemann JH, Lovett FA, Cobb LJ, Pell JM.

J Cell Sci. 2009 Sep 1;122(Pt 17):3104-12. doi: 10.1242/jcs.045757. Epub 2009 Aug 4.

11.

IGF-independent effects of insulin-like growth factor binding protein-5 (Igfbp5) in vivo.

Tripathi G, Salih DA, Drozd AC, Cosgrove RA, Cobb LJ, Pell JM.

FASEB J. 2009 Aug;23(8):2616-26. doi: 10.1096/fj.08-114124. Epub 2009 Mar 30.

PMID:
19332648
12.

Antibodies as molecular mimics of biomolecules: roles in understanding physiological functions and mechanisms.

Hill RA, Flint DJ, Pell JM.

Adv Physiol Educ. 2008 Dec;32(4):261-73. doi: 10.1152/advan.90130.2008.

13.

Convergence of Igf2 expression and adhesion signalling via RhoA and p38 MAPK enhances myogenic differentiation.

Lovett FA, Gonzalez I, Salih DA, Cobb LJ, Tripathi G, Cosgrove RA, Murrell A, Kilshaw PJ, Pell JM.

J Cell Sci. 2006 Dec 1;119(Pt 23):4828-40. Epub 2006 Nov 14.

14.

The role of insulin-like growth factor binding proteins in development.

Pell JM, Salih DA, Cobb LJ, Tripathi G, Drozd A.

Rev Endocr Metab Disord. 2005 Aug;6(3):189-98. Review. No abstract available.

PMID:
16151623
15.

Insulin-like growth factor-binding protein-5 induces a gender-related decrease in bone mineral density in transgenic mice.

Salih DA, Mohan S, Kasukawa Y, Tripathi G, Lovett FA, Anderson NF, Carter EJ, Wergedal JE, Baylink DJ, Pell JM.

Endocrinology. 2005 Feb;146(2):931-40. Epub 2004 Nov 18.

16.

Akt2, a novel functional link between p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in myogenesis.

Gonzalez I, Tripathi G, Carter EJ, Cobb LJ, Salih DA, Lovett FA, Holding C, Pell JM.

Mol Cell Biol. 2004 May;24(9):3607-22.

17.

Partitioning of IGFBP-5 actions in myogenesis: IGF-independent anti-apoptotic function.

Cobb LJ, Salih DA, Gonzalez I, Tripathi G, Carter EJ, Lovett F, Holding C, Pell JM.

J Cell Sci. 2004 Apr 1;117(Pt 9):1737-46. Epub 2004 Mar 9.

18.

Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice.

Salih DA, Tripathi G, Holding C, Szestak TA, Gonzalez MI, Carter EJ, Cobb LJ, Eisemann JE, Pell JM.

Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4314-9. Epub 2004 Mar 9.

19.

Evidence implicating a mid-region sequence of IGFBP-3 in its specific IGF-independent actions.

Hollowood AD, Stewart CE, Perks CM, Pell JM, Lai T, Alderson D, Holly JM.

J Cell Biochem. 2002;86(3):583-9.

PMID:
12210764
20.

Regulation of IGF-I mRNA by GH: putative functions for class 1 and 2 message.

O'Sullivan DC, Szestak TA, Pell JM.

Am J Physiol Endocrinol Metab. 2002 Aug;283(2):E251-8.

22.

Horse conceptuses secrete insulin-like growth factor-binding protein 3.

Herrler A, Pell JM, Allen WR, Beier HM, Stewart F.

Biol Reprod. 2000 Jun;62(6):1804-11.

PMID:
10819785
23.

Enhancement of Insulin-Like Growth Factor I Activity by Novel Antisera: Potential Structure/Function Interactions1.

Pell JM, Hill RA, Stewart CE, Weston CR, Flick-Smith HC.

Endocrinology. 2000 Feb 1;141(2):741-751. doi: 10.1210/endo.141.2.7324. No abstract available.

PMID:
28200821
24.

Enhancement of insulin-like growth factor I activity by novel antisera: potential structure/function interactions.

Pell JM, Hill RA, Stewart CE, Weston CR, Flick-Smith HC.

Endocrinology. 2000 Feb;141(2):741-51.

PMID:
10650956
25.

Identification of proteins in the equine embryonic capsule.

Herrler A, Stewart F, Crossett B, Pell JM, Ellis PD, Beier HM, Allen WR.

J Reprod Fertil Suppl. 2000;(56):601-6.

PMID:
20681175
26.

Overexpression of insulin-like growth factor-II in transgenic mice is associated with pancreatic islet cell hyperplasia.

Petrik J, Pell JM, Arany E, McDonald TJ, Dean WL, Reik W, Hill DJ.

Endocrinology. 1999 May;140(5):2353-63.

PMID:
10218989
27.

Active and inhibitory components of the insulin-like growth factor binding protein-3 protease system in adult serum, interstitial, and synovial fluid.

Maile LA, Xu S, Cwyfan-Hughes SC, Fernihough JK, Pell JM, Holly JM.

Endocrinology. 1998 Dec;139(12):4772-81.

PMID:
9832413
28.

The interaction between nutritional status and growth hormone in young cattle: differential responsiveness of fat and protein metabolism.

Dawson JM, Greathead HM, Craigon J, Hachey DL, Reeds PJ, Pell JM, Buttery PJ.

Br J Nutr. 1998 Mar;79(3):275-86.

PMID:
9577306
31.

Immunological manipulation of growth.

Pell JM.

Proc Nutr Soc. 1997 Jul;56(2):621-30. Review. No abstract available.

PMID:
9264112
32.

Actions of an IGF-I-enhancing antibody on IGF-I pharmacokinetics and tissue distribution: increased IGF-I bioavailability.

Hill RA, Flick-Smith HC, Dye S, Pell JM.

J Endocrinol. 1997 Jan;152(1):123-30.

PMID:
9014847
34.
35.

The developmental regulation of a novel muscle LIM-protein.

Morgan MJ, Madgwick AJ, Charleston B, Pell JM, Loughna PT.

Biochem Biophys Res Commun. 1995 Jul 26;212(3):840-6.

PMID:
7626119
36.

Further characterisation of an IGF-I enhancing antibody: actions on IGF-I-induced hypoglycaemia and interaction with the analogue LR3IGF-I.

Pell JM, Flick-Smith HC, Dye S, Hill RA.

Prog Growth Factor Res. 1995;6(2-4):367-75. Review.

PMID:
8817680
37.

Interactions between growth hormone and nutrition in hypophysectomized rats: body composition and production of insulin-like growth factor-I.

Bates PC, Loughna PT, Pell JM, Schulster D, Millward DJ.

J Endocrinol. 1993 Oct;139(1):117-26.

PMID:
8254284
38.
40.

Differential regulation of IGF-I leader exon transcription.

Pell JM, Gilmour RS.

Adv Exp Med Biol. 1993;343:13-23.

PMID:
8184734
41.
42.

Expression of a growth hormone-responsive exon of the ovine insulin-like growth factor-I gene.

Saunders JC, Dickson MC, Pell JM, Gilmour RS.

J Mol Endocrinol. 1991 Dec;7(3):233-40.

PMID:
1777044
43.
45.

Growth, body composition, hormonal and metabolic status in lambs treated long-term with growth hormone.

Pell JM, Elcock C, Harding RL, Morrell DJ, Simmonds AD, Wallis M.

Br J Nutr. 1990 May;63(3):431-45.

PMID:
2200505
46.

The nutritional regulation of growth hormone action.

Pell JM, Bates PC.

Nutr Res Rev. 1990 Jan;3(1):163-92. doi: 10.1079/NRR19900011. No abstract available.

PMID:
19094337
47.

Potentiation of growth hormone activity in sheep using monoclonal antibodies.

Pell JM, Johnsson ID, Pullar RA, Morrell DJ, Hart IC, Holder AT, Aston R.

J Endocrinol. 1989 Feb;120(2):R15-8.

PMID:
2647887
48.

Relationship between glutamine concentration and protein synthesis in rat skeletal muscle.

Jepson MM, Bates PC, Broadbent P, Pell JM, Millward DJ.

Am J Physiol. 1988 Aug;255(2 Pt 1):E166-72.

PMID:
3136658
49.
50.

Leucine and alpha-ketoisocaproate metabolism and interconversions in fed and fasted sheep.

Pell JM, Caldarone EM, Bergman EN.

Metabolism. 1986 Nov;35(11):1005-16.

PMID:
3773720

Supplemental Content

Support Center